Mereo BioPharma
1 Cavendish Place
London
W1G 0QF
United Kingdom
Tel: 44-0-333-0237-300
Website: http://www.mereobiopharma.com/
About Mereo BioPharma
Mereo is a UK-based specialty biopharma company established to address the R&D and financial challenges faced by an increasing number of large pharma and biotech companies. Mereo’s business model brings clear benefits to these companies, to investors, and to patients.YEAR FOUNDED:
2015
LEADERSHIP:
Co-Founder and CEO: Dr. Denise Scots-Knight
CFO and COO: Richard Bungay
Co-Founder and GC: Charles Sermon
Co-Founder and CMO: Dr. Alastair MacKinnon
Co-Founder and Head of Corporate Development: John Richard
PIPELINE:
Please click here for Mereo's pipeline.
85 articles about Mereo BioPharma
-
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
4/3/2024
Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 10:15am ET / 03:15pm BST.
-
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
3/27/2024
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2023, and provided an update on recent corporate highlights.
-
Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
3/5/2024
Mereo BioPharma Group plc announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 at 11:20am ET / 03:20pm GMT.
-
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
1/8/2024
Mereo BioPharma Group plc, a clinical-stage biopharmaceutical company focused on rare diseases, provided an update on its pipeline programs as well as an update on recent corporate developments.
-
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
10/14/2023
Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc announced interim data from the Phase 2 portion of the Phase 2/3 Orbit study demonstrating that treatment with setrusumab significantly reduced incidence of fractures in patients with OI with at least 6 months of follow-up and continues to demonstrate ongoing and meaningful improvements in lumbar spine bone mineral density.
-
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
9/21/2023
Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a Fireside Chat at the 2023 Cantor Global Healthcare Conference on Wednesday, September 27, 2023 at 10:55am ET / 03:55pm BST.
-
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
9/7/2023
Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 and provided an update on recent corporate highlights.
-
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
6/5/2023
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) today announced data from the dose-selection Phase 2 portion of the Phase 2/3 Orbit study showing that setrusumab rapidly induced bone production in OI-affected patients.
-
Mereo BioPharma to Present at the 2023 Jefferies Healthcare Conference
5/31/2023
Mereo BioPharma Group plc announced that Dr. Denise Scots-Knight, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Thursday, June 8, 2023 at 09:30am ET / 01:30pm GMT.
-
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
5/23/2023
Mereo BioPharma Group plc announced that data from the Phase 2 “ASTRAEUS” trial of alvelestat for the treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease, as well as post-hoc analyses demonstrating the association between biomarker reductions with alvelestat and improvements in SGRQ were presented for the first time to the scientific community at the 2023 American Thoracic Society International Conference.
-
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5/5/2023
Mereo BioPharma Group plc today announced that it has received approval from Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) from the Nasdaq Global Market to the Nasdaq Capital Market.
-
Following recent meetings with the FDA and European Medicines Agency, Mereo Biopharma is designing a Phase III study of alvelestat to treat alpha-1-antitrypsin deficiency-associated lung disease.
-
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
2/8/2023
Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 01:00pm GMT / 08:00am ET.
-
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
11/8/2022
Mereo BioPharma Group plc today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022 at 12:55pm GMT / 07:55am ET.
-
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
10/28/2022
Mereo to Appoint Four New Directors to its Board of Directors.
-
Mereo and Rubric Capital Management settled their proxy battle, entering a cooperation agreement. As a result, Rubric withdrew its notice for a General Meeting of shareholders.
-
Mereo BioPharma to Host Alvelestat R&D Update Call on October 31, 2022
10/24/2022
Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or “the Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that it will host a R&D update call on Monday, October 31, 2022 at 8:00 am ET on the alvelestat (MPH966) program for alpha-1-antitrypsin deficiency (AATD).
-
The proxy battle between Mereo BioPharma and Rubric Capital Management will come to a head on Nov. 18. Mereo issued a shareholder circular on Friday.
-
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
10/21/2022
Mereo BioPharma Group plc (NASDAQ: MREO), (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced it has filed and mailed a shareholder circular (the “Shareholder Circular”) and related meeting and proxy materials in connection with its upcoming General Meeting of Shareholders (the “General Meeting”) to be held on November 18, 2022 at 2:00 p.m. London time.
-
Mereo BioPharma will cut 40% of its headcount and significantly reduce expenses to support the advancement of its lead programs through the clinic.